The Evaluation and Management of Dyslipidemia in HIV-Infected Patients
A metabolic syndrome of insulin resistance, obesity, hypertension, and dyslipidemia is quite common and is a significant risk factor for CHD. HIV-treatment-associated fat-redistribution syndrome with dyslipidemia is similar in appearance to this "metabolic syndrome" observed in non-HIV-infected people. Thus, it is important to review the epidemiology, pathogenesis, diagnosis, and management of HIV-treatment-associated dyslipidemia to alert clinicians and patients about this emerging problem.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)